• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vivlodex (meloxicam)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vivlodex (meloxicam)

  • Profile

Profile

Contact Information

Contact: Assertio Therapeutics
Website: http://www.vivlodex.com/

Currently Enrolling Trials

    Show More

    General Information

    Vivlodex (meloxicam) is a non-steroidal anti-inflammatory.

    Vivlodex is specifically indicated for the management of osteoarthritis pain.

     

    Mechanism of Action

    Vivlodex (meloxicam) is a non-steroidal anti-inflammatory. It has analgesic, anti-inflammatory and antipyretic properties. The mechanism of action of Vivlodex, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

    Side Effects

    Adverse effects associated with the use of Vivlodex may include, but are not limited to, the following:

    • Diarrhea
    • Nausea
    • Abdominal discomfort

    Vivlodex comes with a boxed warning of the potential for nonsteroidal anti-inflammatory drugs (NSAIDs) to cause an increased risk of serious cardiovascular and gastrointestinal events.

    Dosing/Administration

    Vivlodex is supplied as a capsule for oral administration. The recommended starting dose is 5 mg orally once daily. The dose may be increased to 10 mg in patients who require additional analgesia. Use the lowest effective dose for shortest duration consistent with individual patient treatment goals.

    Clinical Trial Results

    FDA Approval

    The FDA approval of Vivlodex was supported by data from a Phase 3, multicenter, double-blind, placebo-controlled study of 402 patients, ages 40 and older, with pain due to osteoarthritis of the knee or hip, who were randomized to receive treatment with once-daily Vivlodex 5 mg, Vivlodex 10 mg or placebo over a period of 12 weeks. The Vivlodex doses studied achieved efficacy at 33 percent lower doses than currently available meloxicam products.

     

     

     

    Approval Date: 2015-10-01
    Company Name: Iroko Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing